Modeling the benefits and costs of integrating an acceptable HLA mismatch allocation model for highly sensitized patients

Transplantation

Volumn 97, Issue 7, 2014, Pages 769-774

  Nguyen, Hung Do ^a,b   Wong, Germaine ^c,d   Howard, Kirsten ^c   Claas, Frans H J ^e   Craig, Jonathan C ^c,d   Fidler, Samantha ^f,g   D'Orsogna, Lloyd ^f,g   Chapman, Jeremey R ^d   Irish, Ashley ^a,h   Ferrari, Paolo ^a,h   Christiansen, Frank T ^f,g   Lim, Wai H ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h FREMANTLE HOSPITAL   (Australia)

Author keywords

Acceptable mismatch; Cost effectiveness analysis; Highly sensitized; HLAMatchmaker; Kidney transplantation

Indexed keywords

ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; FEMALE; GRAFT RECIPIENT; HEALTH CARE ACCESS; HEALTH CARE COST; HLA MISMATCH; HLA TYPING; HOSPITAL ADMISSION; HUMAN; KIDNEY DONOR; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE;

EID: 84897477865     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438639.36838.ac     Document Type: Article

References (26)

1. Lim W, Chadban S, Clayton P, et al. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure and death independent of initial immunosuppression in renal transplant recipients. Clin Transplant 2012; 26: 428.
2. Clayton P, Campbell S, Hurst K, et al. The 35th Annual ANZDATA Report 2012: Chapter 8, Transplantation. Adelaide, South Australia: Australia & New Zealand Dialysis & Transplant Registry; 2012. Available at http://www.anzdata.org.au/anzdata/AnzdataReport/35thReport/2012- annual-report.pdf. Accessed December 4, 2013.
3. Wright J, Narayan S, Collier K. Analysis of kidney allocation during 2011. Sydney, Australia: The Transplantation Society of Australia and New Zealand; 2012. Available at http://www.tsanz.com.au/downloads/ 2011NOMSAnalysis.pdf. Accessed December 3, 2013.
4. Meier-Kriesche H-U, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88: 23.
5. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
6. van den Berg-Loonen EM, Billen EVA, Voorter CEM, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
7. Eng HS, Bennett G, Bardy P, et al. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009; 70: 595.
8. Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay. Transplantation 2006; 82: 1524.
9. Riethmüller S, Ferrari-Lacraz S, Müller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
10. Claas FHJ, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
11. Claas FHJ, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447.
12. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Third edition. New York: Oxford University Press; 2005.
13. Oosterlee A, Rahmel A. Eurotransplant International Foundation Annual Report; 2011.
14. Russ G, Excell L, Hee K. The 35th Annual ANZDATA Report 2012: Chapter 9 Organ Procurement; 2012 June.
15. Dankers MKA, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77: 1236.
16. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
17. Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 2003; 75: 884.
18. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847.
19. Kosmoliaptsis V, Bradley J, Sharples L. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85: 1817.
20. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
21. Australian Institute of Health and Welfare. Dialysis and kidney transplantation in Australia: 1991-2010; 2012.
22. Kidney Health Australia. The economic impact of end-stage kidney disease in Australia: projections to 2020; 2010.
23. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book; 2012 Nov 27.
24. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS) [cited 2012 01/11/2012]; Available from: http://www.pbs.gov.au/pbs/home.
25. Australian Institute of Health andWelfare. Health expenditure Australia 2010-11; 2012 Sep.
26. TreeAge Software Inc. TreeAge Pro Suite 2013. 2013.